Winch Advisory Services LLC Boosts Position in Stryker Co. (NYSE:SYK)

Winch Advisory Services LLC raised its holdings in shares of Stryker Co. (NYSE:SYK) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,732 shares of the medical technology company’s stock after acquiring an additional 39 shares during the period. Stryker makes up about 1.4% of Winch Advisory Services LLC’s portfolio, making the stock its 16th biggest position. Winch Advisory Services LLC’s holdings in Stryker were worth $5,304,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in SYK. Avestar Capital LLC grew its holdings in shares of Stryker by 1.1% during the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after purchasing an additional 31 shares during the period. Patrick M Sweeney & Associates Inc. lifted its position in Stryker by 1.5% in the third quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock valued at $793,000 after buying an additional 32 shares during the last quarter. Grimes & Company Inc. boosted its stake in Stryker by 0.4% during the third quarter. Grimes & Company Inc. now owns 8,239 shares of the medical technology company’s stock worth $2,977,000 after buying an additional 33 shares during the period. Moran Wealth Management LLC raised its stake in shares of Stryker by 0.4% in the 3rd quarter. Moran Wealth Management LLC now owns 9,047 shares of the medical technology company’s stock valued at $3,268,000 after acquiring an additional 34 shares during the period. Finally, Salem Investment Counselors Inc. lifted its holdings in shares of Stryker by 0.5% in the 4th quarter. Salem Investment Counselors Inc. now owns 7,547 shares of the medical technology company’s stock worth $2,719,000 after acquiring an additional 35 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Up 1.5 %

SYK stock opened at $368.09 on Thursday. The company’s 50 day moving average is $375.13 and its two-hundred day moving average is $358.25. Stryker Co. has a twelve month low of $307.23 and a twelve month high of $398.20. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock has a market cap of $140.32 billion, a P/E ratio of 39.45, a PEG ratio of 2.51 and a beta of 0.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the previous year, the company earned $2.46 earnings per share. Stryker’s quarterly revenue was up 11.9% compared to the same quarter last year. Research analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.91%. Stryker’s payout ratio is 36.01%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Royal Bank of Canada restated an “outperform” rating and set a $425.00 price target on shares of Stryker in a research report on Tuesday, January 7th. Wells Fargo & Company raised their price objective on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. upped their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Tuesday, January 7th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.